Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.

Autor: Perusini MA; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Novitzky-Basso I; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Atenafu EG; Biostatistic Department, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Forrest D; Leukemia/BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada., Bence-Bruckler I; Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Savoie L; University of Calgary, Alberta Health Services, Calgary, Alberta, Canada., Keating MM; Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada., Busque L; Hematopoiesis and Aging Research Unit, University of Montreal, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada., Delage R; Centre Universitaire d'Hématologie et d'Oncologie de Québec, CHU de Québec, Hôpital de l'Enfant-Jésus, Quebec City, Quebec, Canada., Xenocostas A; Division of Hematology, Department of Medicine, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada., Liew E; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada., Laneuville P; Division of Hematology, McGill University Health Centre, Montreal, Quebec, Canada., Paulson K; CancerCare Manitoba, Winnipeg, Manitoba, Canada., Stockley T; Department of Pathology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada., Lipton JH; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Leber B; Department of Medicine, McMaster University, Hamilton, Ontario, Canada., Kim DDH; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Department of Hematology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.

Publikováno v: British journal of haematology [Br J Haematol] 2023 Dec; Vol. 203 (5), pp. 781-791. Date of Electronic Publication: 2023 Sep 11.

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Autor: McLaughlin, P, Grillo-López, A J, Link, B K, Levy, R, Czuczman, M S, Williams, M E, Heyman, M R, Bence-Bruckler, I, White, C A, Cabanillas, F, Jain, V, Ho, A D, Lister, J, Wey, K, Shen, D, Dallaire, B K

Publikováno v: Journal of Clinical Oncology; 1/10/2023, Vol. 41 Issue 2, p154-162, 9p

Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study.

Autor: Chruscinski A; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Juvet S; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Moshkelgosha S; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Renner E; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Lilly L; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Selzner N; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Bredeson C; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Grant D; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Adeyi O; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Fischer S; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Demetris AJ; Department of Pathology, University of Pittsburgh, Pittsburgh, PA., Zhang J; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Epstein M; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Macarthur M; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Clement AM; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Khalili K; Department of Medical Imaging, University Health Network, Toronto, ON, Canada., Allan D; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Altouri S; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Bence-Bruckler I; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Cattral M; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Fulcher J; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Galvin Z; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Ghanekar A; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Greig P; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Huebsch L; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Humar A; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Kew A; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Kekre N; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Kim TK; Department of Medical Imaging, University Health Network, Toronto, ON, Canada., McDiarmid S; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Martin L; Ottawa Stem Cell Program, Canadian Blood Services, Ottawa, ON, Canada., McGilvray I; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Sabloff M; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada., Sapisochin G; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Selzner M; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Smith R; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Tinckam K; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Yi TJ; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Levy G; Multi Organ Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada., Atkins H; Blood and Marrow Transplant Program, The Ottawa Hospital, Ottawa, ON, Canada.

Publikováno v: Transplantation [Transplantation] 2022 Mar 01; Vol. 106 (3), pp. 562-574.

BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.

Autor: Kim DDH; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Kim TS; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Atenafu EG; Department of Biostatstics, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Novitzky Basso I; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Forrest D; Leukemia/BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada., Bence-Bruckler I; Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada., Savoie L; University of Calgary, Alberta Health Services, Calgary, AB, Canada., Busque L; Hematopoiesis and Aging Research Unit, University of Montreal, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada., Keating MM; Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada., Delage R; Centre Universitaire d'Hématologie et d'Oncologie de Québec, CHU de Québec, Hôpital de l'Enfant-Jésus, Québec, QC, Canada., Xenocostas A; Department of Medicine, Division of Hematology, London Health Sciences Centre, University of Western Ontario, London, ON, Canada., Liew E; Department of Medicine, University of Alberta, Edmonton, AB, Canada., Paulson K; CancerCare Manitoba, Winnipeg, MB, Canada., Stockley T; Department of Pathology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada., Laneuville P; Division of Hematology, McGill University Health Centre, Montreal, QC, Canada., Lipton JH; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada., Kamel-Reid S; Department of Pathology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada., Leber B; Division of Hematology, Department of Medicine, McMaster University, Hamilton, ON, Canada.

Publikováno v: British journal of haematology [Br J Haematol] 2022 Jan; Vol. 196 (1), pp. 136-145. Date of Electronic Publication: 2021 Sep 08.

Fluorescence In Situ Hybridization Analysis of Complex Translocations in Two Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Patients

Autor: Rajcan-Separovic, E ^*, Bence-Bruckler, I, Wells, P, Wang, H

Publikováno v: In Cancer Genetics and Cytogenetics 1999 114(1):71-74